(Q40403406)

20 September 2017

1 reference

title

Alpha 1-blockers vs 5 alpha-reductase inhibitors in benign prostatic hyperplasia. A comparative review (English)

1 reference

20 September 2017

J T Andersen

1

1 reference

20 September 2017

publication date

1 May 1995

1 reference

20 September 2017

1 reference

20 September 2017

volume

6

1 reference

20 September 2017

issue

5

1 reference

20 September 2017

page(s)

388-396

1 reference

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

20 September 2017

cites work

1 reference

12 December 2020

A Placebo-controlled Double-blind Study of the Effect of Phenoxybenzamine in Benign Prostatic Obstruction

1 reference

12 December 2020

A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia

1 reference

12 December 2020

Prazosin in the Treatment of Prostatic Obstruction A Placebo-controlled Study

1 reference

12 December 2020

Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging

1 reference

12 December 2020

The Natural History of Untreated “Prostatism”

1 reference

12 December 2020

Epidemiology and natural history of benign prostatic hyperplasia.

1 reference

12 December 2020

Urodynamic Effects of Finasteride in the Treatment of Bladder Outlet Obstruction due to Benign Prostatic Hyperplasia

1 reference

12 December 2020

Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation

1 reference

12 December 2020

The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy

1 reference

12 December 2020

New words for old: lower urinary tract symptoms for "prostatism"

1 reference

12 December 2020

Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group

1 reference

12 December 2020

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group

1 reference

12 December 2020

The Assessment of Prostatic Obstruction from Urodynamic Measurements and from Residual Urine

1 reference

12 December 2020

Urodynamics in benign prostatic hyperplasia: a survey.

1 reference

12 December 2020

Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia

1 reference

12 December 2020

Indoramin in the Treatment of Prostatic Bladder Outflow Obstruction

1 reference

12 December 2020

Medical management of benign prostatic hyperplasia

1 reference

12 December 2020

A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction

1 reference

12 December 2020

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up

1 reference

12 December 2020

A new look at bladder neck obstruction by the food and drug administration regulators: guide lines for investigation of benign prostatic hypertrophy

1 reference

12 December 2020

10.2165/00002512-199506050-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1022423805

0 references

1 reference